Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Bayer, BioInvent Extend Licensing Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Bayer, BioInvent Extend Licensing Pact

Expands access to n-CoDeR libraries

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

BioInvent International and Bayer have signed an extension to their 2008 license agreement for the development of antibodies from BioInvent’s n-CoDeR libraries. Under the terms of the extension, Bayer will broaden its access to BioInvent’s discovery and development technology platform. BioInvent will receive an undisclosed license fee to cover new projects plus success-based milestone payments and royalties on products already in development.

The n-CoDeR libraries contain more than 20 billion highly diverse, fully human antibody fragments that have been created using BioInvent’s patented approach, generating antibodies with high affinity and selectivity.

Michael Oredsson, chief executive officer of BioInvent, commented, “The signing of an extension and broadening of our n-CoDeR technology collaboration with Bayer, we believe, exemplifies the value of our technology and the strength of our collaborations. The approach we have taken additionally brings a welcome fillip to our financial resources in a manner consistent with our previously communicated strategy. It is very encouraging to see that our collaborators continue to stay faithful to BioInvent.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics